Publication: Terapéutica y erupción dental en niños con osteogénesis imperfecta
Loading...
Official URL
Full text at PDC
Publication Date
2018
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
Description
UCM subjects
Unesco subjects
Keywords
Citation
1. Hua F, Zhang L, Chen Z. Trigger osteoclast formation and activation: Molecular treatment strategy of delayed tooth eruption. Med Hypotheses. 2007;69(6):1222-1224.
2. Wise GE, Frazier-Bowers S, D'Souza RN. Cellular, molecular, and genetic determinants of tooth eruption. Crit Rev Oral Biol Med. 2002;13(4):323334
3. Stellzig-Eisenhauer A, Decker E, Meyer-Marcotty P, et al. Primary failure of eruption (PFE)--clinical and molecular genetics analysis. J Orofac Orthop. 2010;71(1):6-16
4. Bradaschia-Correa V, Massa LF, Arana-Chavez V. Effects of alendronate on tooth eruption and molar root formation in young growing rats. Cell Tissue Res. 2007;330(3):475-485.
5. Hiraga T, Ninomiya T, Hosoya A, Nakamura H. Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats. Calcif Tissue Int. 2010;86(6):502-510
6. Barbería Leache E. Atlas de odontología infantil para pediatras y odontólogos. 1aed. Madrid: Ripano; 2005. 7. Marks SC, J., Gorski JP, Wise GE. The mechanisms and mediators of tooth eruption--models for developmental biologists. Int J Dev Biol. 1995;39(1):223-230.
8. Burgueño L. Estudio de la erupción de los dientes temporales en una muestra de niños de la comunidad de Madrid(Tesis Doctoral). Madrid: Universidad Complutense de Madrid, Servicio de publicaciones;2014
9. Cahill DR, Marks SC. Tooth eruption: evidence for the central role of the dental follicle. J Oral Pathol Med. 1980; 9:189-200
10. Marks SC, Schroeder HE. Tooth eruption: theories and facts. The Anatomical Record. 1996; 245: 374-93.
11. Fleischmannova J, Matalova E, Sharpe PT, Misek I, Radlanski RJ. Formation of the tooth-bone interface. J Dent Res. 2010;89(2):108-115
12. Huang H, Wang J, Zhang Y, et al. Bone resorption deficiency affects tooth root development in RANKL mutant mice due to attenuated IGF-1 signaling in radicular odontoblasts. Bone. 2017. Article in press.
13. Bègue-Kirn C, Smith AJ, Loriot M, Kupferle C, Ruch JV, Lesot H (1994). Comparative analysis of TGF betas, BMPs, IGF1, msxs, fibronectin, osteonectin and bone sialoprotein gene expression dur- ing normal and in vitro-induced odontoblast differentiation. Int J Dev Biol 38:405-420.
14. Wise GE, King GJ (2008) Mechanisms of tooth eruption and ortho- dontic tooth movement. J Dent Res 87:414–434
15. Bartlett JD, Zhou Z, Skobe Z, Dobeck JM, Tryggvason K (2003). Delayed tooth eruption in membrane type-1 matrix metalloproteinase deficient mice. Connect Tissue Res 44(Suppl 1):300-304.
16. Decker E, Stellzig-Eisenhauer A, Fiebig BS, et al. PTHR1 loss-of- function mutations in familial, nonsyndromic primary failure of tooth eruption. Am J Hum Genet 2008;83:781–6.
17. Gutiérrez-Díez MP, Molina Gutiérrez M,Prieto Tato L, Parra García JI, Bueno Sánchez AM. Osteogénesis Imperfecta: Nuevas Perspectivas. Rev Esp Endocrinol Pediatr 2013; 4 (Suppl)
18. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 2011; 7: 540–57.
19. Rauch F, Munns C, Land C, Glorieux FH. Pamidronate in children and adolescents with osteogenesis imperfecta: Effect of treatment discontinuation. J Clin Endocrinol Metab. 2006;91(4):1268-1274
20. Marini JC, Forlino A, Bächinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052
21. Sillence DO, Rimoin DL, Danks DM. Clinical variability in osteogenesis imperfecta-variable expressivity or genetic heterogeneity. Birth Defects Orig Artic Ser 1979; 15: 113–29
22. AHUCE: Osteogénesis imperfecta (OI). Asociación Nacional de Huesos de Cristal [internet]. Madrid: ahuce;c2007[Actualizado 1 de ene 2018, citado 8 nov 2016] Disponible en: htpp://www.ahuce.org/
23. Hartman J, ed. Osteogenesis Imperfecta: A Guide for Nurses. Bethesda, MD: Osteoporosis and Related Bone Diseases National Resource Center, The National Institutes of Health; 2005
24. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004; 363 (24): 1377– 85.
25. Rios Ródenas M. La unión craneocervical en el paciente con osteogénesis imperfecta. [Tesis Doctoral]. Madrid: Universidad Complutense de Madrid, Servicio de Publicaciones. Servicio de Publicaciones 2016.
26. Gimeno-Martos S, Pérez-Riera C, Guardiola-Vilarroig S, Ca- vero-Carbonell C. Epidemiología de la Osteogénesis Imperfecta: una enfer- medad rara en la Comunitat Valenciana. Rev Esp Salud Pública.2017;91:28
27. Huber M. Osteogenesis imperfecta. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:314-20
28. Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. Osteoporos Int. 2016;27(12):3427-3437
29. Glorieux FH. Osteogénesis Imperfecta. Best Pract Res Clin Rheumatol. 2008;22(1):85-100
30. Wallis GA, Sykes B, Byers PH, Mathew CG, Viljoen D, Beighton P. Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsi- ble. J Med Genet. 1993; 30(6):492–6.
31. Andersson K, Dahllöf G, Lindahl K, et al. Mutations in COL1A1 and COL1A2 and dental aberrations in children and adolescents with osteogenesis imperfecta - A retrospective cohort study. PLoS One. 2017;12(5)
32. Sangsin A, Kuptanon C, Srichomthong C, Pongpanich M, Suphapeetiporn K, Shotelersuk V. Two novel compound heterozygous BMP1 mutations in a patient with osteogenesis imperfecta: A case report. BMC Med Genet. 2017;18(1):25.
33. Majorana A, Bardellini E, Brunelli PC, Lacaita M, Cazzolla AP, Favia G. Dentinogenesis imperfecta in children with osteogenesis imperfecta: a clinical and ultrastructural study. Int J Paediatr Dent. 2010; 20(2): 112-8
34. Hall R, Manière, M, Palamara J, Hemmerle J. Odontoblast dysfunction in osteogenesis imperfecta: an LM, SEM, and ultrastructural study. Connective tissue research. 2002 43(2-3): 401-405.
35. Bart ZR, Hammond MA, Wallace JM. Multi-scale analysis of bone chemistry, morphology and mechanics in the oim model of osteogenesis imperfecta. Connect Tissue Res. 2014;55 Suppl 1:4-8
36. Glorieux, FH, Ward, LM, Rauch, F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. JBMR. 2002 17(1):30-38.
37. Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010; 7(6): 367-81.
38. Janus GJ, Engelbert RH, Beek E, Gooskens RH, Pruijs JE. Osteogenesis imperfecta in childhood: MR imaging of basilar impression. Eur J Radiol. 2003; 47(1): 19-24. 39. O'Connell AC, Marini JC. Evaluation of oral problems in an osteogenesis imperfecta population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;87(2):189-196.
40. Malgrem B, Norgren S. Dental aberrations in children and adolescents with osteogenesis imperfecta. Acta Odontol Scand. 2002;60:65-71
41. Teixeira CS, Santos Felippe MC, Tadeu Felippe W, Silva-Sousa Y, SousaNeto M. The role of dentists in diagnosing osteogenesis imperfecta in patients with dentinogenesis imperfecta. J Am Dent Assoc. 2008;139(7):906-914
42. Muhney K, Campbell PR. Pediatric dental management of a patient with osteogenesis imperfecta and dentinogenesis imperfecta. Spec Care Dentist. 2007;27(6):240-245.
43. Jabbour Z, Al-Khateeb A, Eimar H, et al. Genotype and malocclusion in patients with osteogenesis imperfecta. Orthod Craniofac Res. 2018;21(2):71-77.
44. Grier RL, 4, Wise GE. Inhibition of tooth eruption in the rat by a bisphosphonate. J Dent Res. 1998;77(1):8-15
45. Bradaschia-Correa V, Massa LF, Arana-Chavez V. Effects of alendronate on tooth eruption and molar root formation in young growing rats. Cell Tissue Res. 2007;330(3):475-485.
46. Bradaschia-Correa V, Casado-Gomez I, Moreira MM, Ferreira LB, AranaChavez V. Immunolocalization of smad-4 in developing molar roots of alendronate-treated rats. Arch Oral Biol. 2013;58(11):1744-1750
47. Tuncer I, Delilbasi C, Deniz E, Soluk Tekkesin M, Olgac V, Sencift K. Effects of pamidronate administration on tooth eruption and mandibular growth in new born rats. J Istanb Univ Fac Dent. 2017;51(1):8-14
48. Bhatt RN, Hibbert SA, Munns CF. The use of bisphosphonates in children: Review of the literature and guidelines for dental management. Aust Dent J. 2014;59(1):9-19
49. Soares AP, do Espírito Santo, Renan Fernandes, Line S, et al. Bisphosphonates: Pharmacokinetics, bioavailability, mechanisms of action, clinical applications in children, and effects on tooth development. Environ Toxicol Pharmacol. 2016;42:212-217
50. Devogelaer JP, Malghem J, Maldague B. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16:360–363
51. Glorieux FH, Travers R. Chabot G, Lanoue G.Bone histomorphometric analysis in osteogéne- sis imperfecta. J Bone Miner Res 1994;9 (Suppl 1):S226
52. Grissom LE, Harcke HT. Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol. 2003;33(4):226-229
53. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2- 12.
54. Gavaldá C, Bagán JV. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature. Med Oral Patol Oral Cir Bucal. 2016;21:e260-70. 55. Hoyer-Kuhn H, Franklin J, Allo G, et al. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial. J Musculoskelet Neuronal Interact. 2016;16(1):24-32.
56. Qin H, Xu H, Gong Y. Mechanism of NF-κB signaling pathway and autophagy in the regulation of osteoblast differentiation. Mol Membr Biol. 2016;33(6-8):138-144
57. .McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018
58. Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E. First use of the RANKL antibody deno- sumab in Osteogenesis Imperfecta Type VI. J Muscu- loskelet Neuronal Interact 2012; 12(3):183-188.
59. Walia B, Lingenheld E, Duong L, Sanjay A, Drissi H. A novel role for cathepsin K in periosteal osteoclast precursors during fracture repair. Ann N Y Acad Sci. 2018;1415(1):57-68.
60. Massa LF, Bradaschia-Correa V, Arana-Chavez V. Immunocytochemical study of amelogenin deposition during the early odontogenesis of molars in alendronate-treated newborn rats. J Histochem Cytochem. 2006;54(6):713-725.
61. Kamoun-Goldrat A, Ginisty D, Le Merrer M. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci. 2008;116(3):195-198
62. Vuorimies I et al. Timing of dental development in osteogenesis imperfecta patiens with and without isphosphonate treatment. Bone 2017;94:29-33
63. Bruna M, Gallardo N, Mourelle MR, De Nova MJ. Estudio de la erupción de la dentición permanente en niños y adolescentes de la Comunidad de Masrid (España). Cient Dent. 2012; 9(3):159-64
64. Ferrán Aranaz, M. SPSS para Windows. Programación y Análisis Estadístico. Mc Graw Hill. 1996.
65. Sánchez, M., Frutos, G. y Cuesta, P. L. Estadística y matemáticas aplicadas. Editorial Síntesis. 1996.
66. IBM SPSS. SPSS Statistics 25 Command Syntax Reference. SPSS Inc. 2017. Información de manuales técnicos sobre Análisis estadísticos en http://www-01.ibm.com/support/docview.wss?uid=swg27049428#es